The third phase of vaccination will begin in the country from today, according to which people over the age of 18 will be vaccinated with the Corona vaccine. But many states have urged their citizens not to come to vaccination centers due to the lack of vaccine. Let us know that Kovishield of Serum Institute and Kovaxin of Bharat Biotech are being vaccinated in India.
Covaxin will be produced abroad
At present, many states are facing complaints about a shortage of both vaccines. Therefore, the chief executive of the central government and vaccine institute, Adar Poonawalla, is confirming to increase their vaccine production abroad as well. According to government sources, this decision is taken taking into account the supply crisis.
The need to meet vaccine demand
An official, speaking on condition of anonymity, said that the vaccine demand must be met in light of the new mutation of the Coronavirus. We have offered to make covicin for foreign countries. Production will take place through technical transfer between commercial entities. He further explained that this could be done using other local vaccines.
Explain that last week, the central government awarded Rs 4,500 crore in advance to the Serum Institute and Biotech Bars. On April 20, Bharat Biotech announced that it would increase production of its vaccine to 700 million doses per year.
The serum institute abroad also produces a vaccine
The Covishield vaccine developed by AstraZeneca is produced by the Serum Institute of India. Due to the surge in demand for the vaccine, Institute CEO Adar Poonawala is now planning to produce it overseas as well. However, an official announcement will be made in a few days.
Let’s know that Adar Poonawala reported a few days ago that the Serum Institute will increase its production capacity to 100 million doses by July. Adar Poonawalla hopes to increase the annual production of Kovishield over the next six months from 2.5 billion doses to three billion doses.